Overview

Update
Status
Aerovance has been closed
Total Equity Funding
$98.5M in 3 Rounds from 8 Investors
Headquarters:
Berkeley, California
Description:
Aerovance is a biotech company focused on developing and commercializing medicines for respiratory and allergic diseases.
Founders:
Categories:
Pharmaceutical, Biotechnology, Medical
Website:
http://www.aerovance.com

Company Details

Update
Founded:
2004
Closed:
Closed, Date Unknown
Employees:
1 - 10 | 1 in Crunchbase

Aerovance is a privately held biopharmaceutical company exclusively focused on developing and commercializing breakthrough medicines for respiratory and allergic diseases. The company maintains a solid intellectual property position with its strong portfolio of novel therapeutic candidates now in clinical development and several pre-clinical programs. The two lead products are human recombinant proteins: Aerovantâ„¢, an IL-4 and -13 receptor antagonist which is in Phase IIa studies for asthma and Aerodermâ„¢, a PEGylated IL-4 and IL-13 receptor antagonist in pre-clinical studies for eczema.

Funding Rounds (5) - $120.5M

Update
DateAmount / RoundValuationLead InvestorInvestors
Mar, 2011$500k / Venture0
Sep, 2010$2M / Debt Financing0
Apr, 2009$38M / Venture8
Mar, 2008$20M / Debt Financing2
Mar, 2007$60M / Series C6

News (6)

Update
DateNews
Jan 30, 2014SEC - SEC FORM D
Nov 19, 2013SEC - SEC FORM D
Jun 19, 2009Venture Beat - Aerovance, asthma treatment company, finishes raising $60M
Jun 18, 2009PRNewswire All - Aerovance Secures $20 Million in Debt Financing -- re> BERKELEY, Calif., March 28 /PRNewswire/ --
Apr 10, 2009Venture Beat - Aerovance inhales $38M for asthma drugs
Mar 28, 2007PE HUB - PE HUB

Offices/Locations (1)

Update
  • Headquarters

    2929 7th Street Suite 120

    Berkeley, California 94710

    United States

Add Acquisitions

Add Board Members and Advisors

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Images

Add Videos